Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.50 |
| ▸ | HTR2A | P28223 | 10/20 | 0.50 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23580581 | 0.73 | SMARCA2 (0.48) | HTR2CHTR2A | |
| SCHEMBL27311351 | 0.71 | HTR2A (0.45) | HTR2CHTR2A | |
| SCHEMBL30658007 | 0.67 | BPTF (0.43) | HTR2CHTR2ABPTFCHRM2CHRM4 | |
| SCHEMBL5619809 | 0.67 | HTR2C (1.00) | HTR2CHTR2ACHRM2CHRM4ADRB1 | |
| SCHEMBL5917499 | 0.67 | HTR2C (1.00) | HTR2CHTR2ACHRM2CHRM4ADRB1 | |
| SCHEMBL3983638 | 0.66 | HTR2A (0.58) | HTR2CHTR2A | |
| SCHEMBL5917443 | 0.66 | HTR2C (0.57) | HTR2CHTR2ABPTF | |
| Hydrochloric Acid SCHEMBL5917431 | 0.66 | HTR2C (0.97) | HTR2CHTR2A | |
| SCHEMBL5917472 | 0.66 | HTR2C (0.60) | HTR2CHTR2AADRB1 | |
| SCHEMBL30104846 | 0.65 | HTR2C (0.49) | HTR2CHTR2AADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569485-B2 | SMARCA inhibitors and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | HTR2C 4530/4885HTR2A 4314/4885BPTF 98/4885 |
| US-12569485-B2 | SMARCA inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA2 | HTR2C 2187/4885HTR2A 1885/4885BPTF 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.